PRISM Study: Prostate Recurrence Detection Using Imaging With PSMA PET/MRI Post-high Intensity Focused Ultrasound

Part of paid clinical trials in New York, New York.

Sponsor
NYU Langone Health
Study ID
NCT07184970
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
MALE
Age
40 Years - 95 Years
Healthy Volunteers
Not accepted

Study Details

The purpose of this study is to compare the sensitivity of PSMA PET/MRI and standard MRI in detecting focal therapy failure in the prostate one year after High-Intensity Focused Ultrasound (HIFU) treatment. Specifically, the study aims to evaluate whether PSMA PET/MRI offers a higher sensitivity than MRI alone for identifying recurrence or failure in patients undergoing focal therapy.

Key Dates

Start date
Oct 8, 2025
Status verified
Oct 2025
Primary completion
Oct 1, 2027
Completion
Oct 1, 2028

Study Design

Enrollment
60 participants (estimated)

Arms

  • Arm: Men with Prostate Cancer
    Patients undergoing High-Intensity Focused Ultrasound (HIFU) for focal therapy of prostate cancer. Participants will be followed for one-year post-treatment, with regular monitoring through various clinical assessments.

Primary Outcome Measure

Sensitivity of PSMA PET/MRI [ Time Frame: Month 12 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
NYU Langone HealthNew YorkNew York10016-

Find similar trials in New York, NY

By condition
Prostate cancer
By specialty
OncologyProstate oncologyMen's healthUrology
By research site
NYU Langone Health· New York, NY

Related Studies